



U S A D A

A N N U A L
R E P O R T

2 0 2 3

STANDING ON PRINCIPLE



U.S. Anti-Doping Agency

CONTENTS



Message from the CEO and Board Chair	2
Team USADA	4
2023 By the Numbers	6
Global Clean Sport Advocacy	7
Education	9
TrueSport®	15
Science and Substances	20
Science Serving Sport	22
Advancing Anti-Doping Science	25
Therapeutic Use Exemptions	27
Testing	28
Olympic and Paralympic Anti-Doping Program	29
Client Services	32
Client Testing	33
PFL Anti-Doping Program	34
UFC Anti-Doping Program	35
Doping Control Operations	38
Technology	39
Results Management and Investigations	40
Independent Auditor's Report	43

©2024 USADA. All rights reserved. Permission to reprint or redistribute altered or excerpted materials will be granted on a case-by-case basis. All requests must be made in writing to the U.S. Anti-Doping Agency.

MESSAGE

FROM THE CEO AND BOARD CHAIR

Every year, anti-doping organizations are faced with decisions about how to best protect clean sport and clean athletes. They can pursue the truth and stand on principle, or they can maintain the status quo and let the interests of others guide their choices.

At USADA, we are constantly asking ourselves how our choices align with our values and our commitment to delivering gold-standard anti-doping programs to athletes. These standards require us to look within and beyond, from serving all athletes by employing quality science to both detect intentional doping and exonerate innocent athletes, to taking responsibility for advancing and upholding clean sport around the world, to having the courage to apply the rules equally to all athletes regardless of sport or other interests.

In 2023, standing on principle took many forms, and most notably and most unfortunately, it meant athletes from the UFC were no longer in our program. The relationship between USADA and UFC became untenable after USADA's position of equally applying strong rules was challenged. All athletes' long-term health and safety – in addition to a fair and level playing field – will always be more important to USADA than business opportunities.

We can be proud of the eight years of service we provided to UFC athletes, and we continue looking for every opportunity to serve athletes independent of the influence of sport. That ideal continues to resonate with athletes and sport organizers, including the Professional Fighter's League, which made USADA the independent third-party administrator of its year-round anti-doping program beginning in July 2023.

Our uncompromising commitment to standing on principle was also evident in our global advocacy, including our fierce advocacy for transparency and accountability after athletes' moments were stolen at the 2022 Beijing Olympic Games, when a positive test postponed the medal ceremony and final results for the figure skating team event. In response to athletes' concerns, we also called attention to the terrible reality that elite Russian and Belarus athletes who may compete in Paris have received far less testing than their competitors around the world.

These global failures speak to the desperate need for a more independent and proactive global regulator. In the meantime, we can celebrate and continue to leverage the Rodchenkov Anti-Doping Act (RADA), which allows law enforcement to impose criminal sanctions on individuals involved in doping activities at international events. In 2023, we saw the first defendant charged and convicted under RADA, which led to prison time, for distributing prohibited performance-enhancing drugs to at least four Olympic-level athletes and two coaches.

Of course, we also strive for perfection just like elite athletes and work to hold ourselves accountable to the highest possible standards throughout our education, testing, innovation, and intelligence and results management programs.

MESSAGE

FROM THE CEO AND BOARD CHAIR

In addition to reaching more than 40,000 athletes and other stakeholders with education, we dedicated time to educating and collaborating with National Governing Body and U.S. Olympic & Paralympic Committee staff in 2023 through our Clean Sport Summit. We reached representatives from more than 45 organizations with critical information on ensuring anti-doping compliance and implementing strategies to best serve clean athletes.

While education prepares athletes for their clean sport responsibilities and serves as a deterrence to doping, testing is an integral part of USADA's ability to detect doping and hold accountable those who violate anti-doping rules. In 2023, we collected more than 7,500 samples from Olympic, Paralympic, Pan American, and Parapan American athletes, as well as more than 6,000 samples from athletes across other programs. This testing, along with non-analytical evidence and thorough investigations, led to more than 40 sanctions being announced in 2023.

Science is the backbone of all these operations, allowing USADA to assign the right test to the right athlete at the right time, as well as hold intentional dopers accountable without unfairly punishing innocent athletes. In 2023, we leveraged our scientific expertise to initiate more than 400 science-driven testing and analysis recommendations, while also supporting results management efforts for more than 180 adverse analytical findings and/or other potential anti-doping violations.

Across everything we do, mental health and wellbeing is also a vital consideration. In 2023, for example, we implemented a process to check on athletes' mental well-being after they were notified of a positive test. These types of processes demonstrate our commitment to seeing the person behind each athlete, test, and sanction.

Our youth sport program, TrueSport, also hosted its third annual mental health symposium and commissioned an academic analysis to highlight current challenges in sport that hinder student-athlete mental wellness. This report was released in 2023 and provides a human-centered approach with values-based opportunities for growth and improvement for all stakeholders across sport. This report and a wide range of other resources are shared with a vast network of partners across the youth sport movement. Last year we brought our total number of partners to 83 and our youth sport partner community to more than 17 million.

In 2023 and beyond, we aim to stand on principle at every step—even when it's hard and unpopular. This commitment is what all athletes expect and deserve from us and others to protect them and their sacrifice. As always, we are grateful for the chance to serve clean athletes and stand beside partners that share these values and principles. Thank you to all those who uphold clean, safe, and fair sport.



Dr. Tobie Smith
USADA Board Chair



Travis T. Tygart
USADA CEO

TEAM USADA

BOARD OF DIRECTORS

The USADA Board of Directors is comprised of experienced individuals who share the ideals and principles behind USADA's vision, mission, and core values. Members of the board are independent and thereby cannot serve in any capacity for an organization USADA serves. The Board of Directors advise and support the staff in executing the work of the organization through balanced and diverse perspectives.

For more information on the USADA Board of Directors, please visit www.USADA.org/board-of-directors.



Tobie Smith,
MD, MPH
Chair



Judi Brown Clarke, PhD
Vice Chair



Prof. Timothy Davis
Secretary



Lee Carosi Dunn



Kara Goucher



Alvin M. Matsumoto, MD



Edward J. Merrens, MD



David Plummer,
MBA, MEd



Tim Roemer



Cathy Sellers



Edwin C. Moses, ScD hc
Emeritus Chair

LEADERSHIP

Based in Colorado Springs, Colorado, USADA's leadership team is responsible for managing and coordinating comprehensive and independent anti-doping programs for the U.S. Olympic and Paralympic movements, as well as the Professional Fighters League. USADA's key initiatives include:

- Anti-doping education and resources
- Science, research, and technology projects
- Testing programs
- Results management, investigations, and adjudication

USADA's dedicated and talented team is comprised of more than 100 home-office team members and field-based Doping Control Officers who work collaboratively to realize the organization's mission to:

- Stand with athletes to champion their right to clean sport
- Inspire true and healthy sport
- Promote the integrity of sport

EXECUTIVE LEADERSHIP



Travis T. Tygart
Chief Executive Officer



John Bobo
Chief Operating & Innovation Officer



Sandra Briggs
Chief Financial Officer



Jeff Cook
General Counsel



Matt Fedoruk, PhD
Chief Science Officer



Jennifer Royer, PhD
Senior Director of TrueSport & Awareness

SENIOR LEADERSHIP



Scott Bell
Assistant Controller



Victor Burgos
Chief Investigative Officer



Juan Caraveo
Doping Control Operations Director



David Goldbach
IT Director



Tammy Hanson
Elite Education Director



Laura Lewis, PhD
Director of Science



Shahera Shalabi
Human Resources Director



Lindsey Stafford
Olympic & Paralympic Programs Director



Allison Wagner
Director of Athlete & International Relations



Averi Walker
Communications Director

*Board and staff members include those with USADA at time of publication.

2023 BY THE NUMBERS


EDUCATION

IMPACT

43,933

athletes and stakeholders reached through eLearning, presentations, individual education sessions, booths, webinars, and educational materials.

EDUCATION
TOUCH POINTS: 185



SCIENCE

In 2023, the Drug Reference Line received:

109 drug reference inquiries by phone

413 drug reference inquiries by email

OLYMPIC AND PARALYMPIC MOVEMENT TESTING

7,773 SAMPLES COLLECTED
6,103 TEST SESSIONS COMPLETED
3,011 ATHLETES TESTED
134 EVENTS

CLIENT TESTING

1,869 SAMPLES COLLECTED
1,595 TEST SESSIONS COMPLETED
1,196 ATHLETES TESTED
105 EVENTS

TRUESPORT

TrueSport added **nine** new partners to its network, bringing the total number of partners to

83

and our youth sport partner community to

17.1+M

6,200 INDIVIDUALS ENGAGED

THROUGH **78** EVENTS IN 2023

RESULTS MANAGEMENT

39 SANCTIONS ANNOUNCED IN 2023

UFC ANTI-DOPING PROGRAM
2015 - 2023

29,317 SAMPLES COLLECTED

89% OOC OUT-OF-COMPETITION

11% IC IN-COMPETITION

141 SANCTIONS

PFL ANTI-DOPING PROGRAM

95 SAMPLES COLLECTED

90 TEST SESSIONS COMPLETED

41 ATHLETES TESTED

5 EVENTS



USADA is committed to advocating for clean sport and clean athletes on a global scale. We unite with stakeholders from around the world, including athletes, governments, and national anti-doping organizations (NADOs), to encourage change in the anti-doping movement so that every athlete is confident they are stepping onto a level playing field and every spectator is confident they are witnessing authentic sport achievements.

COMMISSION ON THE STATE OF OLYMPIC AND PARALYMPIC SPORT IN THE U.S.

Congress created the independent Commission on the State of the U.S. Olympics and Paralympics in 2020 to study the United States' participation in Olympic and Paralympic sport. While USADA is not directly under the purview of the study, USADA's CEO, Travis T. Tygart, was invited to provide testimony in the public hearing on Capitol Hill in September of 2023 in a session titled "Athletes' Rights, Equity, and Accessibility and Ensuring Fair Play."

During his testimony, Tygart highlighted the importance of independence and the athlete voice to good governance, noting, "Athletes have come to trust USADA because there is not a single decision we make without first asking, 'Is this best for clean athletes?' We view athletes, and their powerful stories, as our guiding light, our North Star."

The Commission's report, inclusive of findings from the Commission's study and twelve recommendations for next steps to be taken by Congress, was published in early 2024 and can be found at csusop.org.

THE FIRST CRIMINAL SENTENCING UNDER THE RODCHENKOV ANTI-DOPING ACT

The Rodchenkov Anti-Doping Act (RADA) was signed into law on December 4, 2020, and is landmark legislation that allows the U.S. to impose criminal sanctions on individuals involved in doping activities at international events. Eric Lira was the first defendant charged and convicted under RADA for distributing prohibited performance-enhancing drugs to at least four Olympic-level athletes and two coaches.



ADVOCACY FOR CLEAN ATHLETES AT THE 2022 BEIJING OLYMPIC GAMES

USADA has fiercely advocated for transparency and accountability after athletes' moments were stolen at the 2022 Beijing Olympic Games when a positive test postponed the medal ceremony and final results for the figure skating team event. Participants learned on the day of the ceremony that Kamila Valieva, an athlete from Russia, had tested positive in December of 2021. Because regulators failed to process the sample prior to the Games, Valieva was able to compete, and further systematic failures meant that the case wasn't resolved for nearly two years. Not only did U.S. athletes lose their podium moments, but they also lost career opportunities associated with winning an Olympic gold medal.

In January 2024, the Court of Arbitration for Sport imposed a four-year sanction for Valieva.

ADVOCACY FOR ATHLETES AND A LEVEL-PLAYING FIELD AT THE PARIS OLYMPIC AND PARALYMPIC GAMES

In 2023, it was announced that athletes from Russia and Belarus who meet certain criteria may be approved to compete in the 2024 Paris Olympic and Paralympic Games. With that news, Team USA athletes have voiced concerns about the status of anti-doping controls applied to Russian athletes, and USADA has advocated for mandatory third-party testing of every individual athlete from Russia and Belarus who may be approved to compete in Paris. Athletes have expressed concerns because of the history of Russia state-sponsored doping, the non-compliance status of the Russian Anti-Doping Agency, and a 50% decrease in testing of Russian athletes by the

International Testing Agency over the last two years due to the Russian invasion of Ukraine and restricted access to the country. An analysis produced by USADA determined that approximately 75% of 360 Russian summer athletes ranked in the top 10 in their sports since 2021 had been given two or fewer tests in 2023. Based on that data, USADA CEO Travis T. Tygart has stated, "Things are not as they are being portrayed – to say that Russian athletes have been held to the same standards as other athletes is a slap in the face to clean athletes."



EDUCATION




Education is key to doping prevention, which is why USADA provides education to thousands of athletes, coaches, trainers, medical staff, and other athlete support personnel each year. Through in-person and online education, as well as a multitude of other resources, USADA helps ensure that athletes and support personnel have the tools they need to navigate anti-doping rules and responsibilities, while also understanding the role they play in keeping sport clean.

EDUCATION

IMPACT

43,933

athletes and stakeholders reached through eLearning, presentations, individual education sessions, booths, webinars, and educational materials.



eLEARNING EDUCATION	STAKEHOLDERS REACHED
Returning Athlete RTP	899
Returning Athlete CAP	1,020
New Athlete RTP	557
New Athlete CAP	711
HealthPro Advantage	602
Coach's Advantage	375
Weightlifting Coach's Advantage	2,838
Weightlifting Athlete's Advantage	5,754
NSCA Coach's Advantage	328
Swimming Coach's Advantage	16,637
Triathlon Coach's Advantage	14
Athletes Returning from Sanction	9
Client Pay Tutorials	848
Total	30,592

EDUCATION TYPE	STAKEHOLDERS REACHED
Booths	2,223
Face-to-Face	3,495
Materials	2,046
Webinar	1,866
DCO First-Time Education	49
Individual Education Sessions	82
Sanctioned Athlete Calls	23
New Athlete Packets	1,057
Monthly Newsletters	2,500
Total	13,341



BY THE NUMBERS

EDUCATION
TOUCH
POINTS:

185

FACE-TO-FACE

86

46%



WEBINARS

64

35%



BOOTHS

21

11%



MATERIALS ONLY

14

8%

EDUCATION
BY
AUDIENCE:

Category	Junior	Senior	Coaches	Students	Other	Medical	Total Attendance
Face-to-Face	1,795	472	442	50	554	182	3,495
Webinars	1,332	279	162	21	69	3	1,866
Booths	718	157	300	49	982	17	2,223
Materials Only	653	860	233	N/A	216	84	2,046
Totals	4,498	1,768	1,137	120	1,821	286	9,630

Individuals reached
through these modalities
in 2023:

9,630



TUTORIALS

2022

2023

Athlete's Advantage	7,740	8,941
Coach's Advantage	16,995	20,192
HealthPro Advantage	182	602
Other USADA Tutorials	194	857
Total	25,111	30,592



2023 MAJOR CONFERENCES

- Council of Europe
- JCSMS Annual Meeting
- WADA Symposium
- PEERS Conference
- NGB Clean Sport Summit
- Southeast Asia Regional Anti-Doping Organization (SEARADO) Conference

The Elite Education Team continues to invest in athlete education while increasing efforts to engage athlete support personnel, most notably by helping host the National Governing Body (NGB) Clean Sport Summit. We welcomed NGB and USOPC representatives from more than 45 organizations during the two-day “Clean Sport Summit: Strength Through Collaboration.” This summit provided vital updates on anti-doping protocols, celebrated the importance of clean sport, and strengthened the collaborative relationships between USADA and NGB staff. The event successfully reached our organizational goals of deepening and strengthening our relationships with NGBs, educating NGBs on important 2024 changes that are essential for compliance, and aligning strategies to better serve athletes.



MEASUREMENT OF IMPACT

The Elite Education Team continues to gather measurement and evaluative data from audiences after each education session, whether it's virtual, in-person, or through eLearning courses. Our partnership with the University of North Carolina at Greensboro (UNCG) has allowed us to enrich our education practices and develop an updated confidence measure for our in-person and virtual education

sessions. Prior to an education session beginning, an average of 33% of respondents reported feeling 'not confident' or only 'somewhat confident' about the anti-doping topics, compared to more than 87% feeling 'confident' about the same content areas after the session occurred. We regularly review session data to ensure our education practices are in alignment with USADA educational theory and also to identify areas for team growth and where we may celebrate successes. We will continue to gather data from our sessions to ensure we are providing gold-standard educational opportunities to our stakeholders.

AFTER EDUCATION SESSIONS:

87%
of respondents reported feeling '**confident**' about anti-doping topics

PAN AMERICAN AND PARAPAN AMERICAN GAMES IN SANTIAGO

In preparation for the Pan American and Parapan American Games in Santiago, the Elite Education Team worked closely with relevant NGBs to ensure they were prepared as athletes were named to shortlists ahead of the Games. We created Games-specific education sessions, such as the in-person session provided to the USA Gymnastics Men and Women's National Teams, as well as virtual opportunities for USA Shooting, USA Water Polo, and US Rowing. To ensure information was accessible to all stakeholders, we launched a Games landing page on our USADA website and shared out the resource one-pager. We provided a 24/7 hotline service during the period of the Games, where anyone in Santiago could call a USADA

staff member if they had immediate anti-doping needs or concerns. Additionally, we contributed content to the USOPC Games Playbook resource which is designed to guide support staff while at the Games.

In addition, USADA sent 1,000 'Clean Sport Kits' to athletes attending the Games, which were filled with Games-themed educational promotional items, as well as access to clean sport resources and a video message from USADA CEO Travis T. Tygart, which athletes received upon arrival in Santiago. In addition to the educational value, these kits were designed to recognize and celebrate the athletes' hard work and dedication to clean sport.



HEALTH PROFESSIONAL EDUCATION



The Elite Education Team, in collaboration with the Science Team, works diligently to ensure medical professionals have a robust awareness of policies and responsibilities around anti-doping. Attendance at the American College of Sports Medicine Conference and the Joint Commission for Sports Medicine and Science (JCSMS) provided opportunities to connect

with many valuable members of the medical community and has since allowed us to increase our reach to health professionals. Additionally, efforts to work directly with NGB medical staff at USA Volleyball, USA Boxing, and USA Swimming have expanded pathways to educate and provide relevant clean sport resources to medical professionals.

Continued outreach to NGBs has demonstrated a need for further education and resources, which led to the creation of a letter that athletes can give to their medical providers that outlines their anti-doping responsibilities and how providers can help athletes comply with the rules. This letter also helps promote USADA's

HealthPro Advantage eLearning course developed and maintained in partnership with Stanford University School of Medicine. This course has served more than 600 users who have provided great feedback on the course, quality of content delivery, and effectiveness.

EDUCATION

INTERNATIONAL COLLABORATION

In July, Singapore hosted the first Asia-Oceania Anti-Doping Education Symposium and USADA's Dr. Jennifer Royer and Tammy Hanson were invited to present three separate sessions. Their sessions highlighted USADA's approach to curriculum development for elite and youth athletes, as well as the accompanying interactive curriculum mapping and competency rubrics to support global educational standards. Additionally, the presentations detailed specific activities and curricula rooted in values-based education.

Furthermore, phase two of the

WADA Social Science Research grant, awarded in 2021, has begun. Through this project, USADA intends to identify a core set of values that can serve as the foundation for values-based education tailored for athletes and to identify the most salient practice recommendations for values-based education and doping prevention in sport. Phase two of the project entails working with athletes directly to determine if the values identified through the study align with the values those athletes authentically uphold.

ATHLETE PRESENTER PROGRAM AND DCO EDUCATORS

The Athlete Presenter Program continues to support the Elite Education Team in its efforts to provide education and resources to stakeholders. Our Athlete Presenters traveled to events for a wide range of sports, including the National Wheelchair Basketball Association and USA Hockey, to ensure athlete members and athlete support personnel were informed about their anti-doping rights and responsibilities. In June, we onboarded two new presenters, Raymond Bunker, USA Wrestling National Team member, and Carissa Gump, USA Weightlifting Olympian. Raymond and Carissa work with USADA to leverage their own anti-doping perspective and experiences to share meaningful insights while out in the field. We look forward to growing this program, and we are in the process of vetting additional candidates from a promising pool of applicants.

In addition to our Athlete Presenters, a small number of USADA DCOs educate athletes being tested out-of-competition for the first time. Education sessions are conducted prior to testing, which allows athletes to ask questions before the doping control process begins. In 2023, DCO Educators completed 49 sessions, adding to a program total of 196 from its inception in 2020. Based on the success of the program, we are working to grow our network of DCO Educators.



TRUE SPORT



The TrueSport mission is simple and bold: to change the culture of youth sport by providing powerful educational tools to equip young athletes with the resources to build life skills and core values for success - both on and off the field. We're helping to redefine success while also recognizing that the values instilled in the heat of competition resonate far beyond the field, track, or court. TrueSport is the bright light that shines significance on teamwork, perseverance, and respect - pillars that help build champions in the sporting arena, and leaders in the game of life.

TRUESPORT TALKS: MENTAL WELLNESS AND THE MODERN COACH

Today's coaches often feel they face mounting pressures to be all things to all people. These unrealistic expectations placed on a single individual continue to escalate mental wellness challenges for those on the front lines who are leading and inspiring our next generation of great athletes. As national statistics and stories continue to unveil the scope of the national mental health crisis, it was time to implement proactive solutions that allow coaches to prioritize themselves to better serve others.

With this in mind, TrueSport and USADA hosted TrueSport Talks: Mental Wellness and the Modern Coach on November 6, 2023, at the U.S. Olympic & Paralympic Museum.

Emceed by former TrueSport Athlete Ambassador and retired USA Track & Field Olympian, Kara Winger, the hybrid event brought together more than 1,500 registrants and nationally recognized experts in the mental health space to provide workshop sessions on:

- Why coach mental health matters and how to prioritize self to best serve others;
- How to coach hard and still take care of self;
- Effective communication that keeps mental wellness in mind;
- Mental health and emotional regulation;
- Boundaries and balanced identity; and
- Making self-care practical.

This year, TrueSport was excited to collaborate with the U.S. Olympic & Paralympic Committee Psychological Services division in their effort to expand their mental health and performance resources in support of Team USA to sustain competitive excellence. TrueSport also partnered with SportsEngine as the media and streaming partner.

In addition, 75 student-athletes from the Colorado Springs community participated in TrueSport's "Mindset of a TrueSport Champion" program. The 2023 program featured the Children's Hospital of Colorado and the National Strength and Conditioning Association alongside TrueSport Athlete Ambassadors, and guided attendees through activities designed to develop both physical and mental resilience.



TrueSport Talks leverages the insights of subject matter experts to provide evidence-based and practical recommendations to stakeholders.



HUMANIZING SPORT: BEST PRACTICES GUIDE
Coming off the heels of the 2022 TrueSport Talks Mental Wellness Symposium, TrueSport commissioned an academic analysis to highlight current challenges in sport that hinder student-athlete mental wellness. This report was released in 2023 and provides a human-centered approach with values-based opportunities for growth and improvement for all stakeholders across sport.

TRUESPORT CONTENT AND PARTNER PROGRAMS

With a shared vision of sport's ability to enrich the lives of our young people, we partner with organizations across the country that are driven to change sports culture for the better. TrueSport partners with National Governing Bodies (NGBs), International Federations, and youth sport organizations to champion values-based learning through youth sport participation. Each partner customizes the use of TrueSport resources and engagements to meet individual program needs and objectives.

TrueSport Partner Monthly Content Program

Working alongside experts from a wide range of fields, TrueSport publishes practical and evidence-based content on monthly themes like mental wellness, conflict resolution, and nutrition.

In 2023, TrueSport distributed more than **60** articles through our partner content program. In addition, TrueSport added nine new partners to its network, bringing the total number of partners to 83, and our youth sport partner community to **17.1+M**, an increase of about 300,000 from the previous year.

- **83** Total Partners
- **9** New Partners in 2023:
 - USA Curling
 - National Athletic Trainers Association
 - Lakeshore Foundation
 - USA Wheelchair Rugby
 - USA Boccia
 - Los Angeles Bulls Soccer Club
 - Philadelphia Youth Sport Organization
 - Boys & Girls Clubs
 - Colorado High School Cycling League

“WHAT OUR PARTNERS HAVE TO SAY:

“We love TrueSport and all it stands for. The resources are extremely helpful and impactful for our audience. We get great responses no matter what the topic is. Besides just the articles, the TrueSport Talks and other training/info sessions are a great resource and way for our audience to engage in different ways.”

“We love the content that TrueSport provides to us. As a small non-profit, we wouldn't be able to afford getting this important content to our members and broader community... this partnership allows us to bring that content to those who need it.”

Partner Highlight:

KIDS ON BIKES

TrueSport partnered with Kids on Bikes in 2022 to provide values-based education through our content program. What started as an Ambassador visit during “Bike to School” day, has been strengthened through additional programming to include:

1. In-person coaching education for summer camp coaches on how to be more intentional in teaching their athletes about nutrition, hydration, bullying prevention, and perseverance.
2. Selection of one of their coaches and program managers to the Cohort for Change program.



Partner Highlight:

SPORTSENGINE

In addition to supporting TrueSport with the 2023 TrueSport Talks symposium, as well as being a vital content distribution partner, SportsEngine and TrueSport continued the Athlete of the Month program. The Athlete of the Month Program recognizes young athletes who stand out for their contributions to their community alongside their athletic achievements. To recognize and celebrate each month's winner, a TrueSport Athlete Ambassador invited recipients to join them for a virtual interview where Ambassadors personally congratulated them and spent time learning more about them. Each interview was transcribed and shared through the SportsEngine ‘Inside Youth Sports’ newsletter.

2023 TRUESPORT EXPERT PROGRAM

Since its inception in 2020, the TrueSport Expert Program has leveraged the insights and experience of relevant experts, including physicians, psychologists, nutritionists, and social workers, to distinguish TrueSport's content and video resources as reliable, robust, and evidence informed.

The 2023 TrueSport Expert Program included:

KEVIN CHAPMAN, PHD - Licensed Clinical Psychologist, Founder of the Kentucky Center for Anxiety and Related Disorders

MATTHEW FEDORUK, PHD - Chief Science Officer, USADA

DEBORAH GILBOA, MD - Board Certified Family Physician, Parenting & Resilience Expert, Founder of AskDoctorG.com

NADIA KYBA, MSW, RSW - Registered Social Worker, Founder of NowWhatFacilitation.com

MICHELE LABOTZ, MD, FAAP - Sports Medicine Physician, InterMed Sports Medicine Clinic

STEPHANIE MIEZIN, MS, RD, CSSD - Registered Dietitian, Director of Nutrition at KC Current

AMANDA STANEC, PHD - Founder, MOVE+LIVE+LEARN

MELISSA STRENO, PSYD - Licensed Clinical Psychologist, Lantern Psychology

CHARRON SUMLER, LPCC - Athletic Counselor, The Ohio State University Athletics

KRISTEN ZIESMER, MS, RDN, CSSD, LDN - Registered Dietician, Founder of Elite Nutrition and Performance



EVENTS AND ENGAGEMENTS

- TrueSport engaged nearly **6,200** individuals (athletes, coaches, family members, administrators, etc.) either in-person or virtually through **78** different events in 2023.
 - 40 events involved an Athlete Ambassador
 - 7 events involved a TrueSport Expert
 - Highlighted events include:
 - National Recreation and Parks Association Conference
 - US Youth Soccer Grassroots Symposium
 - Broadway Gymnastics School Ambassador Visit
 - M3 Hockey Ambassador Visit
- 40** different external stakeholders collaborated with TrueSport in 2023 by either inviting the team to host a presentation/engagement or co-hosting a presentation/engagement.
 - Highlighted collaborations include:
 - 7 Athlete of the Month Interviews with SportsEngine
 - Joined 6 different sport camps
 - Presented at 10 different conferences
 - Hosted at 14 different schools
 - Provided education sessions for 28 different sport programs (including NGBs, after-school programs, and sport leagues)
 - Hosted 7 trainings for Athlete Ambassadors and Cohort for Change Coaches

TRUESPORT ATHLETE AMBASSADORS

- Athletes who participated in the 2023 Ambassador program included:

TYLER CARTER, Para Alpine Ski (4-year ambassadorship)
STEVE EMT, Wheelchair Curling (2-year ambassadorship)
TREY JENIFER, Wheelchair Basketball (3-year ambassadorship)
MANDY MARQUARDT, Track Cycling (4-year ambassadorship)
CHRIS MAZDZER, Luge (1-year ambassadorship)
AMARA MBIONWU, Netball (4-year ambassadorship)
AMOBI OKUGO, Soccer (1-year ambassadorship)
ABBY RAYMOND, Weightlifting (5-year ambassadorship)
AARON SCHEIDIES, Para Triathlon (3-year ambassadorship)

- Departing athletes at the end of 2023 included:

TYLER CARTER, Para Alpine Skiing
AMARA MBIONWU, Netball



TRUESPORT COHORT FOR CHANGE

The Cohort for Change program brings together coaches and youth sport influencers from across the country to help establish best practices and solutions to further the mission of creating a more positive youth sport experience rooted in mental and physical wellness. Through this program, participants help normalize the conversation around mental wellbeing in sport while integrating age-appropriate tools athletes can use to develop and practice mental wellness - all to help foster a healthy, motivational climate.



The 2023/2024 Cohort for Change includes:

MACY BLAKE, Raleigh, NC
VICTORIA CATES, Los Angeles, CA
ALESHA HARPER, Lancaster, CA
MEGAN MACFARLANE, Moorhead, MN
TELIA MARKS-MCCALL, Pittsfield, MA
KAREN MARLEY, Colorado Springs, CO
KIE MCCRAE, Pittsburgh, PA
MARC MOREAU, Far Hill, NJ
POWELL PAGUIBITAN, Charlotte, NC
EMILY SHIELDS, Colorado Springs, CO
SARAH SUTIN, Park City, UT
RANDY THAMES, Richton Park, IL



THE EXCEPTIONAL INDIVIDUALS IN THIS GROUP REPRESENT 13 DIFFERENT SPORT PROGRAMS AND COME FROM DIVERSE BACKGROUNDS INCLUDING PROFESSIONAL TEACHERS, COACHES, COACH EDUCATORS, AND PROGRAM LEADERS.

SCIENCE AND SUBSTANCES



Science plays a crucial role in the fight for clean competition by driving innovation and evidence-based decision making. At USADA, science and research inform education strategies, testing, and results management operations, while also enhancing detection and deterrence efforts. Through its drug reference initiatives, USADA also provides resources and tools that have a significant impact on the ability of athletes and support personnel to make informed choices about medications and dietary supplements. USADA is also a global leader in anti-doping science, partnering with stakeholders around the world to drive the adoption of athlete-friendly sample collection methods, publish impactful research that supports improvements in detection and deterrence strategies, and develop surveys that yield quality data to advance meaningful change.

HIGHLIGHTS

- **SUCCESSFULLY DELIVERED THE 22ND ANNUAL USADA SYMPOSIUM ON ANTI-DOPING SCIENCE**, themed “Revisiting Oxygen Transport Manipulation and Blood Doping Detection: Who’s Winning?” in Paris, France in collaboration with the French Anti-Doping Agency (AFLD). USADA and AFLD hosted more than 110 attendees from 32 countries.
- **LEVERAGED OUR SCIENTIFIC EXPERTISE TO SUPPORT TESTING STRATEGY**, initiating more than 400 science-driven testing and analysis recommendations, while also supporting results management efforts for more than 180 adverse analytical findings and/or other potential anti-doping violations. Science also leads the Therapeutic Use Exemption (TUE) process, supports investigations, and compiles expert reports and testimony. In 2023, the team conducted two scientific studies that exonerated athletes based on contamination scenarios and published three peer-reviewed papers.



- **PARTNERED WITH THE PARTNERSHIP FOR CLEAN COMPETITION (PCC)** to host a 2023 Conference in New York City and served on the PCC Scientific Advisory Board to review and recommend anti-doping scientific research projects.
- **CONTINUED TO DEVELOP AND REFINE DATA-DRIVEN RISK ASSESSMENT TOOLS** for all individual Olympic and Paralympic sports to guide our testing strategies leading up to the Paris 2024 Olympic and Paralympic Games.
- **CREATED NEW INTERNAL TOOLS** that allow for expeditious review of almost 50,000 athlete declarations of prescription and non-prescription products made on doping control forms.
- **CONTINUED COLLABORATION WITH THE ATHLETICS INTEGRITY UNIT** to collect more than 60 matched capillary and venous blood samples at the Boston Marathon to validate a more athlete-friendly blood collection method using cutting edge technology.



SCIENCE AND SUBSTANCES

TOP 10

Global DRO
ingredient searches
in the U.S. in 2023

- 1 Albuterol (Salbutamol) **5,374**
- 2 Marijuana (THC, Cannabis) **5,144**
- 3 Acetaminophen (Paracetamol, Tylenol) **3,014**
- 4 Creatine **3,010**
- 5 Testosterone **2,044**
- 6 Phenylephrine **1,671**
- 7 Ibuprofen **1,632**
- 8 Caffeine **1,630**
- 9 Pseudoephedrine **1,615**
- 10 Adderall **1,579**

SCIENCE SERVING SPORT

USADA is committed to providing athletes and support personnel with the resources and information they need to uphold clean sport, which means providing the most convenient and accurate information on substances and methods through various channels, including a Drug Reference Line direct to USADA staff, Global Drug Reference Online (Global DRO®), and Supplement Connect®.



Global DRO helps athletes and support personnel identify the prohibited status of medications and ingredients from seven partner countries:

Australia, Canada, Japan, New Zealand, Switzerland, the U.K., and the U.S.

In 2023, the free platform saw **2,313,664** total searches, which included **304,739** searches from the U.S. section of GlobalDRO.com and on the USADA.org website. USADA's app for athletes also led to **4,914** searches on Global DRO.

DRUG REFERENCE LINE

The USADA Drug Reference Team helps athletes navigate the rules around substances and methods by answering questions online and over the phone. In most cases, USADA was able to provide answers back to athletes or athlete support personnel within 24 hours.

In 2023, the Drug Reference Line received:

109 drug reference inquiries by phone

413 drug reference inquiries by email

*Does not include UFC or PFL inquiries



DECLARATION REVIEWS

The team reviewed **49,259** medications and supplements declared on doping control forms across USADA's programs to identify the use of prohibited substances or methods and to help athletes identify if they need to apply for a Therapeutic Use Exemption in certain situations. USADA is one of the few anti-doping organizations that reviews declarations.

32,214

OLYMPIC/PARALYMPIC DECLARATIONS REVIEWED

3% increase from previous year





ATHLETE BIOLOGICAL PASSPORT

The Athlete Biological Passport (ABP) program monitors selected biological parameters in urine and blood samples over time that may indirectly reveal effects of doping on the body. The ABP program allows anti-doping organizations to generate individual, longitudinal data sets for each athlete and to look for any fluctuations that may be indicative of the use of performance-enhancing drugs or methods. This data can also be used to conduct targeted, conventional anti-doping tests on athletes with abnormal characteristics, as well as provide corroborating evidence of doping during an anti-doping rule violation case. The hematological module was launched in 2009, resulting in more than 200 sanctions worldwide, based on ABP blood data alone. The second module of the ABP, the urinary steroid module, was launched in 2014 and is

used primarily to guide special analysis and target testing.

In August 2023, WADA launched the Next Gen ABP module in ADAMS, and with it, a new endocrine ABP module and additional blood steroid markers to support the steroid module. USADA began implementing these new modules in Q4 2023 in accordance with our test distribution plan and risk data driven assessment.

USADA, together with our external Athlete Passport Management Unit (APMU), reviewed 1,489 blood passports and 1,307 steroid passports for the Olympic and Paralympic Anti-Doping Program, as well as 442 blood passports and 699 steroid passports for the UFC Anti-Doping Program, resulting in more than 400 specific testing and further analysis recommendations.

USADA also maintains an in-depth resource, called **Supplement Connect**, to help athletes and support personnel realize, recognize, and reduce the risks from supplements. In 2023, Supplement Connect served more than **7,000** users, with anywhere from **436** to **804** visitors per month.



In 2023, the HRL included products from

397
different companies

937
products on the HRL
at the end of 2023

262
products added to
the HRL in 2023

43
products were archived in
2023 because they are no
longer sold, or they no longer
meet the HRL criteria

The below table lists the number of products on the HRL by WADA Prohibited List category. Products can now have multiple substance classifications since one product may contain multiple prohibited substances or fall under different classifications. For example, higenamine is listed as both a Beta-2 Agonist and a Stimulant.

CLASSIFICATION	NUMBER
S0 Non-Approved Substances	12
S1 Anabolic Agents	421
S2 Peptide Hormones, Growth Factors, Related Substances and Mimetics	32
S3 Beta-2 Agonists	122
S4 Hormone and Metabolic Modulators	117
S5 Diuretics and Masking Agents	1
S6 Stimulants	391
S8 Cannabinoids	1



Products are added to the HRL if they advertise, or if testing reveals, that they contain substances prohibited in sport. The below table lists the number of products added to the HRL by WADA Prohibited List category (some supplements contained ingredients from multiple categories).

CLASSIFICATION	NUMBER
S0 Non-Approved Substances	0
S1 Anabolic Agents	141
S2 Peptide Hormones, Growth Factors, Related Substances and Mimetics	4
S3 Beta-2 Agonists	20
S4 Hormone and Metabolic Modulators	14
S5 Diuretics and Masking Agents	0
S6 Stimulants	99

ADVANCING ANTI-DOPING SCIENCE

USADA SYMPOSIUM ON ANTI-DOPING SCIENCE

Ahead of the 2024 Olympic and Paralympic Games, the first Games to be held in Paris in 100 years, USADA continued its tradition of international scientific collaboration by hosting the 22nd Annual USADA Symposium on Anti-Doping Science in cooperation with AFLD, the French National Anti-Doping Agency, in Paris.

The event, which took place from September 29 to October 1, gathered scientific and medical experts in hematology and anti-doping at the Pullman Paris Centre-Bercy to discuss the theme, "Revisiting Oxygen Transport Manipulation and Blood Doping Detection: Who's Winning?"

Blood doping and the use of prohibited substances to manipulate oxygen transport remain some of the most high-risk performance-enhancing doping agents in sport. Blood doping practices, such as the administration of synthetic erythropoietin (EPO), have led to some of the most well-known doping scandals in modern history, including the investigation of the U.S. Postal Service Pro Cycling Team. Despite the direct and indirect detection strategies in place, more must be done to refine and advance new detection methods.

Knowing that investment in science and research drives progress in anti-doping, USADA and AFLD hosted **110 participants** from **32 countries** and a variety of industries to investigate how blood doping has evolved and discuss innovative solutions to monitor and detect blood doping.



Larry D. Bowers Award for Excellence in Anti-Doping Science

The Symposium also provides the opportunity to recognize and award the achievements of scientists who have made an impact on anti-doping approaches and best practices. USADA was pleased to present the 7th Larry D. Bowers Award for Excellence in Anti-Doping Science to Prof. Giuseppe d'Onofrio and Dr. Yorck Olaf Schumacher for their groundbreaking and significant contribution to the advancement and success of the Athlete Biological Passport.



PARTNERSHIP FOR clean competition

The Partnership for Clean Competition (PCC) is a nonprofit organization supported by USADA and others in the sports world that are devoted to protecting clean sport. The PCC works to protect the integrity of sport and public health by supporting high quality anti-doping research. Anti-doping research is essential to improve both detection and deterrence.

To that end, in 2023 the PCC:

- Accepted **12** projects, including one fellowship
- Recommended **\$1,059,323** in funding through grants and fellowships
- Held **three** Scientific Advisory Board Meetings where new project applications were considered and ongoing projects were reviewed
- Facilitated **24** publications and presentations (11 publications, 13 presentations)
- Celebrated **15** years as an organization
- Brought together anti-doping scientists and administrators from around the world at its first conference since 2019, located at Major League Baseball Headquarters, with:
 - 14 presentations and 40 speakers
 - 118 in-person attendees and 78 virtual attendees



PUBLICATION CONTRIBUTIONS

Detection of capromorelin in urine following oral and dermal routes of administration Sobolevsky T, Walpurgis K, Goergens C, Fedoruk M, Lewis L, Ahrens B, Thevis M., Drug Test Anal. 2023 Sep 8. doi: 10.1002/dta.3573.

Application of micro capillary blood sampling in an anti-doping setting Lewis L, Goodrum J, Cai C, Muir T, Boutard K, Capdevielle T, Longo S, Fedoruk M, Miller G., Drug Test Anal. 2023 Nov 20. doi: 10.1002/dta.3603.

¹³C values of urinary 19-norandrosterone in antidoping samples and potential for adverse findings from boar offal consumption Nair VS, Howa JD, Morrison MS, Beggs L, Campbell T, Fedoruk M, Ahrens B, Eichner D., Drug Test Anal. 2023 Mar 16. doi: 10.1002/dta.3470.

THOUGHT LEADERSHIP

The members of USADA's Science Team are thought leaders in the anti-doping science community, which means they lead and contribute to many studies, committees, and conferences worldwide.

COMMITTEE PARTICIPATION

- IWF Anti-Doping Committee
- WADA Strategic Testing Expert Advisory Group
- WADA Health, Medicine and Research Committee
- WADA Scientific Project Review Working Group
- WADA Contaminants Working Group
- WADA Athlete Biological Passport Steroidal Working Group
- Aquatics Integrity Unit, Anti-Doping Advisory Body
- WADA ABP Hematological Working Group
- WADA ABP Plasma Volume Quantification Working Group
- ITA Pre-Games Testing Expert Group
- IPC Ad hoc Anti-doping Committee member for Parapan American Games, Santiago 2023
- WADA Global Learning and Development Framework (GLDF)
- WADA TUE Technical Working Group

THERAPEUTIC USE EXEMPTIONS

USADA recognizes that athletes, like all people, may have medical conditions or illnesses that require them to receive treatment with a particular medication or undergo medical procedures. If the substance or method prescribed to treat that medical condition is prohibited by the World Anti-Doping Agency (WADA) Prohibited List, athletes can apply for a Therapeutic Use Exemption (TUE), and if granted, obtain permission to use a prohibited substance or method in sport for a specified time period. All TUEs are evaluated according to the WADA International Standard for TUEs (ISTUE) and are subject to mandatory WADA monitoring for compliance.

HIGHLIGHTS

PROCESSED
572 standard
TUEs and

39 retroactive
TUEs in 2023


SUCCESSFULLY
REDUCED THE
PROCESSING TIME
TO AN AVERAGE OF

12 days from receipt
of a complete TUE
Application

Which is far less than the
21-day WADA processing
requirement

RECEIVED
522 TUE Pre-Check
Forms

611 TUE Applications



TOP 5 TUES PROCESSED BY WADA PROHIBITED LIST CATEGORY

REQUESTED TUEs	# OF APPLICATIONS
Stimulants	231
Diuretics and Masking Agents	71
Hormone and Metabolic Modulators	63
Glucocorticoids	62
Anabolic Agents	37

APPROVED TUEs	# OF APPROVALS
Stimulants	140
Diuretics and Masking Agents	55
Hormone and Metabolic Modulators	37
Glucocorticoids	34
Anabolic Agents	19

DENIED TUES	# OF DENIALS
Anabolic Agents	15
Stimulants	7
Diuretics and Masking Agents	6
Peptide Hormones, Growth Factors, Related Substances and Mimetics	5
Hormone and Metabolic Modulators	4

* Charts do not include In-Progress, Not-Needed, Incomplete, and Withdrawn TUEs.

TUE BREAKDOWN BY ATHLETE CLASSIFICATION

ATHLETE CLASSIFICATION	# OF APPLICATIONS	APPROVED	DENIED
Recreational	444	235	30
National/International	155	108	9
TOTAL	599	343	39

* Charts do not include In-Progress, Not-Needed, Incomplete, and Withdrawn TUEs.



TESTING



USADA maintains a gold standard anti-doping program for Olympic, Paralympic, Pan American, and Parapan American sport in the United States. Testing is an integral part of USADA's ability to detect doping and hold accountable those who violate anti-doping rules. Both in-competition (IC) and no-notice, out-of-competition (OOC) testing are part of an effective anti-doping program that protects clean athletes' rights and a level playing field. No-notice OOC testing is facilitated by Whereabouts information that athletes are required to submit on an ongoing basis.

In collaboration with USADA's Science and Results Management Teams, the Olympic and Paralympic Programs Team oversees and strategically allocates resources for IC and OOC testing for Olympic, Paralympic, Pan American, and Parapan American athletes.

BY THE NUMBERS

7,773
SAMPLES COLLECTED

- **6,103** TEST SESSIONS COMPLETED
- **3,011** ATHLETES TESTED
- **134** EVENTS

SAMPLES COLLECTED BY QUARTER

	Q1	Q2	Q3	Q4	TOTALS
Urine	1,229	1,861	1,982	957	6,029
Blood	225	393	348	246	1,212
Serum	44	72	50	73	239
DBS	21	86	135	51	293
TOTALS	1,519	2,412	2,515	1,327	7,773

SAMPLES COLLECTED OUT-OF-COMPETITION (OOC) VS. IN-COMPETITION (IC)

	URINE	BLOOD	SERUM	DBS	TOTALS
OOC	4,299	1,210	197	152	5,858
IC	1,730	2	42	141	1,915
TOTALS	6,029	1,212	239	293	7,773



**TRACKED
2,915**

"long list" athletes
across all sports

18 qualification or
trial events
**FOR A TOTAL OF
228** test
sessions

**COMPLETED
2,627**

tests on long list
athletes from
1/1/23 - 11/26/23

1.39

Average number of
completed tests per
confirmed Santiago athlete

2023 HIGHLIGHT

2023 PAN AMERICAN AND PARAPAN AMERICAN GAMES IN SANTIAGO

The Olympic and Paralympic Team focused on the execution of their strategic testing plan for Pan American and Parapan American Pre-Games testing. This included working closely with the USADA Science Team to execute and coordinate dynamic testing, conduct testing at qualification and trial events, and coordinate with our National Governing Body partners to identify the pathways for being named to Team USA and ensure proper education was administered.

COMPLETION STATUS

2,627 Total Tests

2,210 Urine Tests

291 Blood Tests

47 Serum Tests

79 DBS Tests


SAMPLE ANALYSES

Collaboratively, the USADA Science and Testing Teams work to determine the optimal analyses for each urine, blood, serum, or DBS sample. All samples are analyzed for a standard list of substances (a basic screen) based on whether it's an in-competition or out-of-competition test. In addition, Special Analysis can be performed on top of basic screens to detect specific substances, such as erythropoietin (EPO) and growth hormone (GH), depending on the results of the basic screen and/or assessment of other data. USADA

goes to great lengths to ensure that every sample is analyzed strategically based on intelligence, an athlete's biological passport, the risk of the sport/discipline, and WADA requirements.

The graph below shows the percentage of the most common Special Analyses (by sample type) conducted on USADA samples in 2023. For example, ESA analysis was conducted on 18% of all USADA urine samples. Overall, **15,397** analyses were performed on athlete samples.

PERCENTAGE OF TEST TYPE SAMPLES



2023 TESTING NUMBERS BY SPORT

SPORT	TOTAL OOC	TOTAL IC	TOTAL TESTS
Archery	22	14	36
Artistic Swimming	13	0	13
Badminton	9	0	9
Basque Pelota	1	0	1
Biathlon	75	12	87
Bobsled and Skeleton	83	0	83
Bowling	5	0	5
Boxing	45	9	54
Canoe and Kayak	9	27	36
Climbing	33	0	33
Curling	0	13	13
Cycling	507	216	723
Dance Sport	10	0	10
Diving	24	8	32
Equestrian	6	0	6
Fencing	28	0	28
Field Hockey	25	27	52
Figure Skating	56	12	68
Golf	4	0	4
Gymnastics	78	22	100
Ice Hockey	31	0	31
Judo	47	25	72
Karate	24	25	49
Luge	11	0	11
Modern Pentathlon	11	6	17
Paralympic Alpine Skiing	17	0	17
Paralympic Archery	9	6	15
Paralympic Badminton	4	0	4
Paralympic Basketball	37	0	37
Paralympic Boccia	8	0	8
Paralympic Canoe	2	0	2
Paralympic Cycling	175	27	202
Paralympic Equestrian	2	0	2
Paralympic Fencing	1	0	1
Paralympic Goalball	6	0	6
Paralympic Judo	14	4	18
Paralympic Nordic Skiing	2	2	4
Paralympic Powerlifting	18	0	18
TOTALS	5,858	1,915	7,773

WHEREABOUTS

Whereabouts information is critical to USADA's ability to conduct strategic no-notice, out-of-competition testing. Athletes in USADA's Registered Testing Pool (RTP) submit quarterly Whereabouts filings and are responsible for providing updates to USADA when their schedule changes, whether it be documenting previously unplanned travel or adding a new training location or competition. Athletes in USADA's Clean Athlete Program (CAP) are subject to limited Whereabouts requirements that better align with their doping risk and type of testing. Both pools are subject to the same education requirements, which includes an annual online education tutorial. Athletes in both the RTP and CAP have numerous ways to communicate their Whereabouts to USADA.



Number of
Whereabouts
Updates
Received via
Website and App

186,245

Number of Unique
(RTP or CAP)
Athletes who
Submitted Updates
via Website and App

2,997

CLIENT SERVICES



USADA provides gold-standard testing services to sports organizations and event organizers worldwide. Various organizations within the Olympic/Paralympic community utilize USADA to conduct their testing, including National Governing Bodies, National Anti-Doping Organizations, the International Testing Agency (ITA), and International Federations. USADA also seeks to proactively build relationships outside of the Olympic/Paralympic community in order to cultivate new business opportunities and pursue our mission across a diverse range of sports as more organizations recognize the long-term benefits of deterring and detecting doping in their sports.



1,869

SAMPLES
COLLECTED

1,595

TEST SESSIONS
COMPLETED

1,196

ATHLETES
TESTED

105

EVENTS

SAMPLES COLLECTED
OUT-OF-COMPETITION (OOC)
VS. IN-COMPETITION (IC)

	URINE	BLOOD	SERUM	DBS	TOTALS
OOC	661	263	141	63	1,128
IC	716	0	21	4	741
Totals	1,377	263	162	67	1,869

SAMPLES COLLECTED
BY QUARTER

	URINE	BLOOD	SERUM	DBS	TOTALS
Q1	355	47	46	2	450
Q2	365	82	19	41	507
Q3	331	32	39	1	403
Q4	326	102	58	23	509
Totals	1,377	263	162	67	1,869

2023 HIGHLIGHT
FISU WINTER WORLD UNIVERSITY GAMES

The Client Services Team successfully completed testing at the 2023 FISU Winter World University Games, held in Lake Placid, New York from January 12-22, 2023. Testing was conducted in two cities over **13** days and at multiple locations. During this timeframe, USADA collected a total of **210** samples, which included urine and serum samples from both pre-competition and in-competition testing.



PFL ANTI-DOPING PROGRAM

One of the most significant events for Client Services in 2023 was finalizing a five-year agreement and launching the Professional Fighter's League Anti-Doping Program. It was a team effort to propose and execute an impactful program that will bring clean sport to the league.

The PFL is the second leading MMA professional sport organization in the world and has the third largest fan base with roughly 630 million fans. The PFL's competition format features a regular season of 6 events, 3 win-or-go-home playoff fights, and a championship fight per weight class with a \$1 million payout for each winner. In addition to the PFL regular season, the PFL has PFL PPV Super Fights, two PFL International Leagues, and Bellator.

This year-round, comprehensive, and gold standard program includes education, Therapeutic Use Exemptions, Whereabouts, testing both domestically and internationally, investigations, and results management. The PFL's investment in this program speaks to the value of an independent and harmonized anti-doping program built on integrity and excellence.

Following the program launch on July 1, 2023, USADA onboarded and educated fighters, conducted out-of-competition testing, planned and carried out testing for the 3 playoff fights, and completed in-competition testing for the 2023 World Championship fight on November 24, 2023.

HIGHLIGHTS


95
**SAMPLES
COLLECTED**


90
**TEST SESSIONS
COMPLETED**

41
**ATHLETES
TESTED**

EDUCATION

In addition to completing all onboarding education sessions, USADA answered **318** email inquiries about the prohibited status of substances and methods.

Global DRO also saw **462** searches related to the PFL program.



SAMPLES COLLECTED OUT-OF-COMPETITION (OOC) VS. IN-COMPETITION (IC)

	URINE	BLOOD	SERUM	TOTALS
OOC	24	3	2	29
IC	54	0	12	66
Totals	78	3	14	95

RESULTS MANAGEMENT

ADVERSE FINDINGS AND OTHER DOPING VIOLATIONS INITIATED IN 2023



5
**Potential
Doping
Violations**

- 0 Cases Initiated in 2023 Resulting in a Sanction
- 3 Cases Resulting in No Violation
- 2 Cases Pending at End of 2023

POTENTIAL VIOLATIONS AND OTHER DOPING VIOLATIONS BY SUBSTANCE CATEGORY

1 S4 - HORMONE AND METABOLIC MODULATORS

4 S8 - CANNABINOIDS



U F C

ANTI-DOPING PROGRAM



The groundbreaking USADA/UFC Anti-Doping Program began in 2015 and set a new standard for anti-doping in professional sports before concluding on December 31, 2023. The program resonated deeply with athletes and fostered a culture of clean sport championed by the fighters themselves. By 2023, an overwhelming 87% of UFC athletes emphasized the significance of participating in a robust, year-round anti-doping initiative, underscoring its pivotal role in upholding safety, fairness, and honesty in the sport. USADA continually strived to ensure that the program was as cutting-edge as possible by adopting athlete-friendly rule sets, innovative testing methodologies, and the latest technologies. All the while, USADA maintained the highest standards of independence, transparency, and accountability.



U F C

ANTI-DOPING PROGRAM

29,317 SAMPLES COLLECTED




141 SANCTIONS

TESTING POOL GROWTH


ROSTER SIZE

Contract roster size: 550 >



PROGRAM OVERVIEW 2015 - 2023

COMPLETED TEST SESSIONS BY COUNTRY



INNOVATION HIGHLIGHTS

PROGRESSIVE RULE CHANGES

- Implemented Decision Concentration Levels (DCL) to select substances in recognition that analysis methods can increasingly detect trace levels of substances in an athlete's system that are there not from intentional doping but from innocent sources of contamination that have not provided any performance advantage. If a positive test fell under the DCL, it was treated as an atypical finding, meaning it was not treated as a violation unless more evidence showed that the athlete intentionally or recklessly consumed a product containing the prohibited substance.
- Implemented a Certified Supplement program, meaning no violation was imposed if a positive test was caused by contaminated certified supplements. This program provided significant incentive for athletes to use third-party certified supplements that are safer and far less likely to contain prohibited substances.
- Implemented rules specific to SARMS and GW1516 to ensure that positive tests for these substances within a certain concentration range led to less significant suspensions given their prevalence in contaminated products.

GLOBAL CONSISTENCY

A wide network of sample collection personnel and a robust test planning system allowed USADA to ensure that athletes were tested equally no matter where they lived, trained, and competed.

TECHNOLOGY

USADA implemented innovative collection methods, including Dried Blood Spot (DBS) testing, which enabled more athlete-friendly blood collection and allowed the UFC to continue blood collections during the COVID pandemic and become the first professional sport to return to competition.

RESULTS MANAGEMENT

ADVERSE FINDINGS AND OTHER DOPING VIOLATIONS INITIATED IN 2023



63

Potential Doping Violations

5	Cases Initiated in 2023 Resulting in a Sanction
54	Cases Resulting in No Violation
4	Cases Pending at End of 2023



2023 HIGHLIGHTS

640 athletes in RTP at beginning of 2023

4,279 samples collected

131 athletes added to RTP

58 nationalities

131 new athlete education calls

in 8 languages

10,169 Global DRO searches

100% Whereabouts compliance

THERAPEUTIC USE EXEMPTIONS

7	3	1	1
APPROVED	DENIED	NOT NEEDED	WITHDRAWN

POTENTIAL VIOLATIONS AND OTHER DOPING VIOLATIONS BY SUBSTANCE CATEGORY

Athlete Biological Passport	1	S2 - Peptide Hormones, Growth Factors, Related Substances, and Mimetics	2	S6 - Stimulants	1
Non-Analytical	1	S7 - Narcotics	1	S8 - Cannabinoids	14
SO - Non-Approved Substances	1	S4 - Hormone and Metabolic Modulators	7	M2 - Chemical and Physical Manipulation	1
S1 - Anabolic Agents	30	S5 - Diuretics and Masking Agents	12		

*Several cases involved more than one Prohibited Substance, Prohibited Method, and/or Anti-Doping Policy Violation

DOPING CONTROL OPERATIONS

13,910
SAMPLES COLLECTED

4,707
ATHLETES TESTED

65
DOMESTIC DCOS

16
INTERNATIONAL DCOS

BY THE NUMBERS


OPERATIONS

USADA partnered with Ember LifeSciences, an innovator in the pharmaceutical cold chain industry and creator of the award-winning Ember Cube, to enhance the efficiency of the blood sample shipping processes. With its ability to bring improved visibility and accountability into the cold chain, the Ember Cube was used by USADA at several prestigious sporting events in 2023, including the Boston and New York Marathons and the IRONMAN World Championship in Kona. The Professional Fighters League also became the first MMA promotion to use the new technology for a fight in November. USADA was able to monitor the real-time location, ambient temperature, and payload temperature of the Cubes during transit, ensuring that the blood samples maintained optimal temperatures and chain of custody was retained throughout the journey.

This partnership also forced the development of the new Innovero blood tube security kit due to the space capacity inside the Ember Cube. The new blood kit was trialed at the Boston Marathon and officially launched in the field in Q3 2023.

USADA employs more than 75 highly trained Doping Control Officers (DCOs) across the country and the world who receive extensive training and evaluation on all aspects of the sample collection process. DCOs are also a resource for athletes and help them properly complete all sample collection paperwork.

TESTING NUMBERS BY SPORT



EDUCATION

Education plays a pivotal role in the professional development of DCOs, providing them with the necessary knowledge and skills to effectively carry out their roles in maintaining integrity and fairness in sports. DCOs take six meticulously crafted eLearning courses designed to provide comprehensive insights and practical knowledge on the following topics:

- Dried Blood Spot Collection Procedures
- Failure to Comply
- Record Testing
- Shipping and Logistics for DC Ops
- Declarations and Anti-Doping Resources for Athletes
- In-Competition Best Practices and Sample Collection Policy Review

TECHNOLOGY



ATHLETE CONNECT



OVERVIEW

In anticipation of the 2024 Olympic and Paralympic Games in Paris, USADA has innovated a suite of technological advancements aimed at enhancing the athlete experience. These include a paperless collection system, a user-friendly web-based application for educational resources and Whereabouts reporting, and a cutting-edge data analytics platform designed to revolutionize service delivery to athletes.



USADA is invested in using innovative technologies to facilitate efficient, effective, and intelligent anti-doping operations, as well as implementing cutting-edge technologies that streamline and improve the athlete experience.

2023 ACHIEVEMENTS

- Successfully implemented a new paperless collection system to streamline the process for Doping Control Officers.
- Launched the innovative Athlete Connect progressive web application, integrating educational modules with simplified systems for athlete Whereabouts.
- Pioneered a state-of-the-art data analytics platform, delivering it a full year ahead of the projected timeline.
- Strengthened our technological and service capabilities by appointing a new IT Director and expanding our data analytics team.

RESULTS

MANAGEMENT & INVESTIGATIONS



USADA is charged with handling the results management and adjudication process for U.S. athletes in Olympic, Paralympic, Pan American, and Parapan American sport. This independence removes the inherent conflict of interest associated with sport organizations trying to both promote and police their sports. USADA's process affords a full and fair legal process to athletes and support personnel.

39

SANCTIONS
ANNOUNCED
IN 2023

ADVERSE FINDINGS AND OTHER DOPING
VIOLATIONS INITIATED IN 2023

POTENTIAL DOPING VIOLATIONS 96

Number of Cases Referred to International Federations or Anti-Doping Organizations	1
Number of Cases Initiated in 2023 Resulting in a Sanction	18
Number of Cases Resulting in No Violation	51
Number of Cases Pending at End of 2023	26



RESULTS MANAGEMENT

POTENTIAL VIOLATIONS AND OTHER DOPING VIOLATIONS BY SUBSTANCE CATEGORY

CATEGORY	NUMBER
Athlete Biological Passport	3
Non-Analytical	7
S1 Anabolic Agents	17
S2 Peptide Hormones, Growth Factors, Related Substances, and Mimetics	9
S3 Beta-2 Agonists	2
S4 Hormone and Metabolic Modulators	6
S5 Diuretics and Masking Agents	20
S6 Stimulants	14
S7 Narcotics	3
S8 Cannabinoids	4
S9 Glucocorticoids	6
M1 Manipulation of Blood and Blood Components	5
M2 Chemical and Physical Manipulation	8

*Several cases involved more than one Prohibited Substance, Prohibited Method, and/or Anti-Doping Rule Violation

WHEREABOUTS FAILURES

In 2023, USADA created a new role on its Results Management Team dedicated to the management of potential Whereabouts Failures. Adding this role under the Results Management Team allowed USADA to centralize and streamline the Whereabouts Failure program to best serve athletes going through the results management process. A Whereabouts Failure (Filing Failure or Missed Test) can result from an athlete's failure to file or update their required Whereabouts information or from an unsuccessful test attempt caused by inaccurate or insufficient Whereabouts information.

USADA issued **426** potential Whereabouts Failure notices across the Olympic, Paralympic, and UFC programs, of which **322** were declared to be Whereabouts Failures and **104** were determined not to be Whereabouts Failures upon a detailed review of the circumstances of each attempt and submissions from athletes.

INTELLIGENCE

Under the WADA International Standards for Testing and Investigations, USADA and other Anti-Doping Organizations are required to have processes in place that facilitate the ability to gather intelligence from analytical and non-analytical information. Many of USADA's investigations stem from tips provided through the Play Clean Tip Center. Through this platform, USADA makes available numerous ways to report the abuse of performance-enhancing drugs in sport. In addition to ensuring that tips can be submitted anonymously, USADA handles all tips in a secure and systematic manner to assess their reliability, relevance, and accuracy.



BY THE NUMBERS

396

TOTAL TIPS
(ALL PROGRAMS)

LEADING TO

3

**NON-ANALYTICAL
CASES**

43

**TEST REFERRALS TO USADA
AND OTHER ANTI-DOPING
ORGANIZATIONS**

**THESE TEST REFERRALS
LED TO 2 MORE CASES**

3

**SANCTIONS RESULTED FROM
INTELLIGENCE AND INVESTIGATIONS**

INDEPENDENT AUDITORS REPORT

CONTENTS

Independent Auditor's Report	1
Financial Statements	2
Statements of Financial Position	2
Statements of Activities	3
Statement of Functional Expenses - Year Ended December 31, 2023	4
Statement of Functional Expenses - Year Ended December 31, 2022	5
Statements of Cash Flows	6
Notes to Financial Statements	7

Independent Auditor's Report

Board of Directors
United States Anti-Doping Agency
Colorado Springs, Colorado

Report on the Audit of the Financial Statements

Opinion

We have audited the financial statements of United States Anti-Doping Agency, which comprise the statements of financial position as of December 31, 2023 and 2022, and the related statements of activities, functional expenses and cash flows for the years then ended, and the related notes to the financial statements.

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of United States Anti-Doping Agency as of December 31, 2023 and 2022, and the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS) and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States (*Government Auditing Standards*). Our responsibilities under those standards are further described in the "Auditor's Responsibilities for the Audit of the Financial Statements" section of our report. We are required to be independent of United States Anti-Doping Agency and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation and maintenance of internal controls relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about United States Anti-Doping Agency's ability to continue as a going concern within one year after the date that these financial statements are available to be issued.

Board of Directors
United States Anti-Doping Agency

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS and *Government Auditing Standards* will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS and *Government Auditing Standards*, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of United States Anti-Doping Agency's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about United States Anti-Doping Agency's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Board of Directors
United States Anti-Doping Agency

Supplementary Information

Our audits were conducted for the purpose of forming an opinion on the financial statements as a whole. The schedule of expenditures of federal awards as required by Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards*, is presented for purposes of additional analysis and is not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with GAAS. In our opinion, the schedule of federal awards is fairly stated in all material respects in relation to the financial statements as a whole.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated May 30, 2024 on our consideration of the United States Anti-Doping Agency's internal controls over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements and other matters. The purpose of that report is to describe the scope of our testing of internal controls over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Agency's internal controls over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Agency's internal controls over financial reporting and compliance.

FORVIS, LLP

Colorado Springs, Colorado
May 30, 2024

United States Anti-Doping Agency

Statements of Financial Position
December 31, 2023 and 2022

Assets

	2023	2022
Current Assets		
Cash	\$ 4,851,745	\$ 5,691,154
Accounts receivable, net of allowance; 2023 - \$3,700 and 2022 - \$2,004	1,089,218	1,022,062
Grants receivable	1,928,177	3,144,297
Investments	5,464,523	1,903,810
Supplies	191,984	257,973
Prepaid expenses and other	<u>619,581</u>	<u>752,062</u>
Total current assets	<u>14,145,228</u>	<u>12,771,358</u>
Noncurrent Assets		
Investment in InnoVero, LLC	782,217	714,165
Long-term certificate of deposit	229,256	-
Right-of-use assets - operating leases	297,177	631,169
Property and equipment, net	<u>10,889</u>	<u>22,610</u>
Total noncurrent assets	<u>1,319,539</u>	<u>1,367,944</u>
Total assets	<u><u>\$ 15,464,767</u></u>	<u><u>\$ 14,139,302</u></u>

Liabilities and Net Assets

Current Liabilities		
Accounts payable and other accrued liabilities	\$ 2,397,495	\$ 2,851,131
Deferred revenue	359,668	217,601
Current maturities of operating lease liabilities	<u>332,497</u>	<u>373,270</u>
Total current liabilities	<u>3,089,660</u>	<u>3,442,002</u>
Noncurrent Liabilities		
Operating lease liabilities, net of current portion	<u>11,872</u>	<u>344,369</u>
Total liabilities	<u>3,101,532</u>	<u>3,786,371</u>
Net Assets Without Donor Restrictions		
Undesignated	9,613,235	7,602,931
Board-designated	<u>2,750,000</u>	<u>2,750,000</u>
Total net assets without donor restrictions	<u>12,363,235</u>	<u>10,352,931</u>
Total liabilities and net assets	<u><u>\$ 15,464,767</u></u>	<u><u>\$ 14,139,302</u></u>

See Notes to Financial Statements

United States Anti-Doping Agency
Statements of Activities
Years Ended December 31, 2023 and 2022

	2023	2022
Revenues, Grants and Other Support		
Without Donor Restrictions		
ONDCP federal grant	\$ 15,250,000	\$ 15,000,000
United States Olympic and Paralympic Committee (USOPC) contractual agreement	6,600,000	5,207,580
Revenue from testing and other services	8,896,974	8,590,874
Change in equity investment in InnoVero, LLC	64,627	34,666
Net investment return	362,094	(313,183)
Other loss	<u>(7,806)</u>	<u>(6,560)</u>
 Total revenues, grants and other support without donor restrictions	 <u>31,165,889</u>	 <u>28,513,377</u>
Expenses		
Program expenses		
Testing services	18,650,007	18,274,562
Results management	2,800,825	2,848,930
Science, research and development and drug reference	2,613,851	2,835,059
Education and awareness	<u>3,311,729</u>	<u>3,341,821</u>
 Total program expenses	 27,376,412	 27,300,372
General and administrative	<u>1,779,173</u>	<u>1,818,614</u>
 Total expenses	 <u>29,155,585</u>	 <u>29,118,986</u>
Change in Net Assets Without Donor Restrictions	2,010,304	(605,609)
Net Assets Without Donor Restrictions, Beginning of Year	<u>10,352,931</u>	<u>10,958,540</u>
Net Assets Without Donor Restrictions, End of Year	<u>\$ 12,363,235</u>	<u>\$ 10,352,931</u>

See Notes to Financial Statements

United States Anti-Doping Agency

Statement of Functional Expenses

Year Ended December 31, 2023

	Program Services					Support Services	
	Science, Research and Development and Drug Reference				Total Program	General and Administrative	Total Expenses
	Testing	Results	Management	Education and Awareness			
Salaries and benefits	\$ 5,010,626	\$ 2,079,456	\$ 1,557,279	\$ 2,192,994	\$ 10,840,355	\$ 1,123,057	\$ 11,963,412
Sample collection and analysis	6,487,935	-	41,253	-	6,529,188	-	6,529,188
Professional services	543,900	528,425	594,987	561,362	2,228,674	217,399	2,446,073
Travel	2,009,287	86,254	66,469	153,901	2,315,911	81,201	2,397,112
Information technology	3,581,576	72,300	71,983	72,248	3,798,107	78,572	3,876,679
Occupancy, utilities and administrative expenses	927,848	19,912	27,028	31,337	1,006,125	224,697	1,230,822
Offices expenses	32,657	7,315	26,011	24,355	90,338	23,418	113,756
Conferences, conventions and meetings	17,487	2,304	218,193	191,086	429,070	9,721	438,791
Other expenses	38,691	4,859	10,648	84,446	138,644	21,108	159,752
Total expenses	\$ 18,650,007	\$ 2,800,825	\$ 2,613,851	\$ 3,311,729	\$ 27,376,412	\$ 1,779,173	\$ 29,155,585

See Notes to Financial Statements

United States Anti-Doping Agency
Statement of Functional Expenses
Year Ended December 31, 2022

	Program Services					Support Services	
	Science, Research and Development and				Total Program	General and Administrative	Total Expenses
	Testing	Results	Management	Drug Reference			
Salaries and benefits	\$ 4,730,951	\$ 1,958,308	\$ 1,427,532	\$ 2,064,091	\$ 10,180,882	\$ 1,168,972	\$ 11,349,854
Sample collection and analysis	6,856,705	-	42,312	-	6,899,017	-	6,899,017
Professional services	891,836	726,518	1,064,648	749,814	3,432,816	241,951	3,674,767
Travel	2,276,245	66,858	60,759	148,164	2,552,026	47,917	2,599,943
Information technology	2,349,981	56,269	49,085	120,654	2,575,989	86,359	2,662,348
Occupancy, utilities and administrative expenses	920,926	23,306	23,306	23,306	990,844	221,069	1,211,913
Offices expenses	107,633	9,360	13,180	18,182	148,355	15,118	163,473
Conferences, conventions and meetings	108,261	4,058	144,034	116,929	373,282	20,374	393,656
Other expenses	32,024	4,253	10,203	100,681	147,161	16,854	164,015
Total expenses	\$ 18,274,562	\$ 2,848,930	\$ 2,835,059	\$ 3,341,821	\$ 27,300,372	\$ 1,818,614	\$ 29,118,986

See Notes to Financial Statements

United States Anti-Doping Agency

Statements of Cash Flows

Years Ended December 31, 2023 and 2022

	2023	2022
Operating Activities		
Change in net assets	\$ 2,010,304	\$ (605,609)
Items not requiring (providing) cash		
Depreciation and amortization	11,721	15,768
Noncash operating lease expense	333,992	323,152
Net realized and unrealized losses (gains)	(217,696)	343,104
Change in equity investment in InnoVero, LLC	(64,627)	(34,666)
Changes in		
Accounts receivable	(67,156)	(273,581)
Grants receivable	1,216,120	(558,374)
Supplies	65,989	339
Prepaid expenses and other	129,056	(158,196)
Accounts payable and other accrued liabilities	(453,636)	322,938
Operating lease liability	(373,270)	(351,245)
Deferred revenue	<u>142,067</u>	<u>46,761</u>
Net cash provided by (used in) operating activities	<u>2,732,864</u>	<u>(929,609)</u>
Investing Activities		
Purchase of investments	(4,594,985)	(740,209)
Proceeds from sale of investments	1,022,712	710,287
Contribution paid to equity investee	<u>-</u>	<u>(200,079)</u>
Net cash used in investing activities	<u>(3,572,273)</u>	<u>(230,001)</u>
Decrease in Cash	(839,409)	(1,159,610)
Cash, Beginning of Year	5,691,154	6,850,764
Cash, End of Year	<u>\$ 4,851,745</u>	<u>\$ 5,691,154</u>
Supplemental Cash Flow Information		
Cash paid for amounts included in the measurement of lease liabilities		
Operating cash flows from operating leases	\$ 389,694	\$ 378,508

United States Anti-Doping Agency

Notes to Financial Statements
December 31, 2023 and 2022

Note 1: Nature of Operations and Summary of Significant Accounting Policies

Nature of Operations

United States Anti-Doping Agency (the Agency) began operations October 1, 2000. The Agency is responsible for testing, education, research and adjudication for U.S. Olympic and Paralympic athletes, Pan American Games, and the Ultimate Fighting Championship. The Agency is also responsible for enhancing research efforts and promoting educational programs to inform athletes of the rules governing the use of performance-enhancing substances, the ethics of doping and its harmful health effects.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues, expenses, gains, losses and other changes in net assets during the reporting period. Actual results could differ from those estimates.

Cash

At December 31, 2023, the Agency's cash accounts exceeded federally insured limits by approximately \$4,602,000. Uninvested cash included in investment accounts are not considered to be cash for financial reporting purposes.

Accounts Receivable

Accounts receivable are stated at the amount of consideration from customers, of which the Agency has an unconditional right to receive plus any accrued and unpaid interest. The Agency provides an allowance for doubtful accounts, which is based upon a review of outstanding receivables, historical collection information and existing economic conditions. Delinquent receivables are written off based on individual credit evaluation and specific circumstances of the customer.

Contract Assets

Contract assets are recorded when the Agency has a right to consideration in exchange for goods or services that the Agency has transferred to the customer.

Investments

The Agency measures securities, other than investments that qualify for the equity method of accounting, at fair value.

United States Anti-Doping Agency

Notes to Financial Statements
December 31, 2023 and 2022

Net Investment Return

Investment return includes dividend, interest, and other investment income; realized and unrealized gains and losses on investments carried at fair value; and realized gains and losses on other investments, less external and direct internal investment expenses. Gains and losses on the sale of securities are recorded on the trade date and are determined using the specific identification method.

Supplies

Supplies consist of drug testing kits and other doping control supplies and are valued at the lower of cost (first-in, first-out method) or net realizable value.

Property and Equipment

Property and equipment are recorded at cost, less accumulated depreciation. Depreciation and amortization are calculated using the straight-line method over the following estimated useful lives:

Computer equipment and software	3 – 5 years
Furniture, fixtures and office equipment	5 – 7 years
Website development	3 years
Lab equipment	5 years

Leasehold improvements are amortized over the term of the leases or the estimated lives of the improvements, whichever is shorter.

Deferred Revenue

Deferred revenue includes revenues received, which have not yet been used for their specified period.

Net Assets

Net assets, revenues, gains and losses are classified based on the existence or absence of donor- or grantor-imposed restrictions.

Net assets without donor restrictions are available for use in general operations and not subject to donor or certain grantor restrictions. The governing board has designated, from net assets without donor restrictions, net assets for research and contingencies.

Net assets with donor restrictions are subject to donor- or certain grantor-imposed restrictions. The Agency does not have any donor-restricted net assets.

United States Anti-Doping Agency

Notes to Financial Statements
December 31, 2023 and 2022

Federal Grants and Grants Receivable

Support funded by grants is recognized as the Agency performs the contracted services or incurs outlays eligible for reimbursement under the grant agreements. Expenses incurred but not reimbursed are recorded as grants receivable. Grant activities and outlays are subject to audit and acceptance by the granting agency and, as a result of such audit, adjustments could be required. The value recorded for the federal grants is recognized as follows:

Nature of the Gift	Value Recognized
<i>Conditional gifts without restriction</i>	
Gifts that depend on the Agency overcoming a donor-imposed barrier to be entitled to the funds	Not recognized until the gift becomes unconditional, <i>i.e.</i> , the donor-imposed barrier is met

United States Olympic and Paralympic Committee (USOPC) Contractual Agreement and Testing Services Revenue

USOPC contractual agreement and testing services revenue is recognized as the Agency satisfies performance obligations under its contracts. Revenue is reported at the estimated transaction price or amount that reflects the consideration to which the Agency expects to be entitled in exchange for providing goods or services. The Agency determines the transaction price based on standard charges for goods and services provided. The Agency determines its estimates implicit price concessions based upon historical experience.

Income Taxes

The Agency is exempt from income taxes under Section 501(c)(3) of the Internal Revenue Code and a similar provision of state law. However, the Agency is subject to federal income tax on any unrelated business taxable income.

Functional Allocation of Expenses

The costs of supporting programs and activities have been summarized on a functional basis in the statements of activities. The statements of functional expenses present the natural classification detail of expenses by function. Certain costs have been reasonably allocated among the program and management and general categories based on the percentage of effort, percentage of utilization and other methods.

United States Anti-Doping Agency

Notes to Financial Statements
December 31, 2023 and 2022

Change in Accounting Principle

Effective January 1, 2023, the Agency adopted ASU 2016-13, *Financial Instrument – Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments*, related to the impairment of financial instruments. This guidance, commonly referred to as current expected credit loss (CECL), changes impairment recognition to a model that is based on expected losses rather than incurred losses. The measurement of expected credit losses under the CECL methodology is applicable to financial assets measured at amortized cost, including trade receivables.

Adoption of the standard did not have significant impact on the financial statements.

Note 2: Disclosures About Fair Value of Assets and Liabilities

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurements must maximize the use of observable inputs and minimize the use of unobservable inputs. There is a hierarchy of three levels of inputs that may be used to measure fair value:

- Level 1** Quoted prices in active markets for identical assets or liabilities
- Level 2** Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities in active markets; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities
- Level 3** Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities

United States Anti-Doping Agency

Notes to Financial Statements

December 31, 2023 and 2022

Recurring Measurements

The following tables present the fair value measurements of assets recognized in the accompanying statements of financial position measured at fair value on a recurring basis and the level within the Topic 820 fair value hierarchy in which the fair value measurements fall at December 31, 2023 and 2022:

	2023					
	Fair Value Measurements Using					
	Quoted Prices					
	in Active Markets for Identical Assets			Significant Other Observable Inputs		
	Fair Value	(Level 1)		Inputs	(Level 2)	Inputs
						(Level 3)
Equity mutual funds						
Large-cap	\$ 805,914	\$ 805,914	\$ -	\$ -		
International	576,296	576,296	-	-		
Small- and mid-cap	131,560	131,560	-	-		
Other mutual funds						
Fixed income bonds	579,451	579,451	-	-		
Real estate	66,394	66,394	-	-		
Money market	2,128,673	2,128,673	-	-		
Certificates of Deposit						
Short-term	917,025	-	917,025	-		
Long-term	229,256	-	229,256	-		
Cash and cash equivalents	5,434,569					
	<u>259,210</u>					
	<u><u>\$ 5,693,779</u></u>					

United States Anti-Doping Agency

Notes to Financial Statements

December 31, 2023 and 2022

	2022				
	Fair Value Measurements Using				
	Quoted Prices				
	in Active Markets for Identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs
	Fair Value	(Level 1)	Fair Value	(Level 2)	(Level 3)
Equity mutual funds					
Large-cap	\$ 530,047	\$ 530,047	\$ -	\$ -	\$ -
International	464,234	464,234	-	-	-
Small- and mid-cap	112,300	112,300	-	-	-
Other mutual funds					
Fixed income bonds	523,020	523,020	-	-	-
Real estate	132,253	132,253	-	-	-
Cash			1,761,854		
			<u>141,956</u>		
			<u><u>\$ 1,903,810</u></u>		

Following is a description of the valuation methodologies and inputs used for assets and liabilities measured at fair value on a recurring basis and recognized in the accompanying statements of financial position, as well as the general classification of such assets and liabilities pursuant to the valuation hierarchy. There have been no significant changes in the valuation techniques during the years ended December 31, 2023 and 2022.

Investments

Where quoted market prices are available in an active market, securities are classified within Level 1 of the valuation hierarchy. Level 1 securities include large-cap, small- and mid-cap, and international equity mutual funds; and real estate and fixed income bond mutual funds. If quoted market prices are not available, then fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows. These are considered Level 2 securities and includes certificates of deposit. In certain cases where Level 1 or Level 2 inputs are not available, securities are classified within Level 3 of the hierarchy. Currently, the Agency does not have Level 3 securities.

United States Anti-Doping Agency

Notes to Financial Statements
December 31, 2023 and 2022

Note 3: Investment in InnoVero, LLC

On February 7, 2019, InnoVero, LLC (InnoVero) was incorporated and on December 31, 2019, the partnership agreement was created and InnoVero became the manufacturer of anti-doping products and practices for athletes. The Agency had a 50% interest in InnoVero at December 31, 2023 and 2022. The investment is accounted for under the equity method. The net income and net loss of InnoVero will be allocated amongst the Agency and the other investor based upon the ownership interest. Financial position and results of operations of the investee are summarized as follows:

	2023	2022
Current assets	\$ 1,163,700	859,561.00
Noncurrent assets	2,618,494	768,284
Total assets	3,782,194	1,627,845
Current liabilities	351,680	231,535
Members' equity	\$ 3,430,514	\$ 1,396,310
Revenues	\$ 2,251,699	\$ 1,997,903
Net income	\$ 129,254	\$ 69,332

The Agency contributed \$0 and \$200,079 during 2023 and 2022, respectively, and recognized income on the investment in equity investee of \$64,627 and \$34,666 at December 31, 2023 and 2022, respectively. The investment balance was \$782,217 and \$714,165 at December 31, 2023 and 2022, respectively.

Note 4: Property and Equipment

Property and equipment at December 31, 2023 and 2022 consists of:

	2023	2022
Computer equipment and software	\$ 577,244	\$ 577,244
Furniture, fixtures and office equipment	64,275	64,275
Leasehold improvements	80,025	80,025
Lab equipment	116,599	116,599
Less accumulated depreciation and amortization	838,143	838,143
	(827,254)	(815,533)
Total property and equipment, net	\$ 10,889	\$ 22,610

United States Anti-Doping Agency

Notes to Financial Statements
December 31, 2023 and 2022

Note 5: Leases

Accounting Policies

The Agency determines if an arrangement is a lease or contains a lease at inception. Leases result in the recognition of ROU assets and lease liabilities on the statements of financial position. ROU assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease, measured on a discounted basis. The Agency determines lease classification as operating or finance at the lease commencement date.

The Agency accounts for lease and nonlease components separately. The Agency allocates the consideration to the lease and nonlease components using their relative standalone values. In addition, the Agency applies a portfolio approach to effectively account for the operating lease ROU assets and liabilities.

At lease commencement, the lease liability is measured at the present value of the lease payments over the lease term. The ROU asset equals the lease liability adjusted for any initial direct costs, prepaid or deferred rent, and lease incentives. The Agency has made a policy election to use a risk-free rate (the rate of a zero-coupon U.S. Treasury instrument) for the initial and subsequent measurement of all lease liabilities. The risk-free rate is determined using a period comparable with the lease term.

The lease term may include options to extend or to terminate the lease that the Agency is reasonably certain to exercise. Lease expense is generally recognized on a straight-line basis over the lease term.

The Agency has elected not to record leases with an initial term of 12 months or less on the statements of financial position. Lease expense on such leases is recognized on a straight-line basis over the lease term.

United States Anti-Doping Agency

Notes to Financial Statements
December 31, 2023 and 2022

Nature of Leases and Quantitative Disclosures

Right-of-use assets, operating leases as of December 31, 2023 and 2022 consist of:

	Asset	
	2023	2022
Office space lease (A)	\$ 270,569	\$ 585,272
Copier lease (B)	26,608	45,897
Right-of-use assets	<u>\$ 297,177</u>	<u>\$ 631,169</u>

Lease liabilities as of December 31, 2023 and 2022 consist of:

	Liability	
	2023	2022
Office space lease (A)	\$ 312,622	\$ 666,603
Copier lease (B)	31,747	51,036
Less current portion	<u>344,369</u>	<u>717,639</u>
Lease liabilities, net of current portion	<u>\$ 11,872</u>	<u>\$ 344,369</u>

- (A) The Agency has entered into an operating lease agreement for office space. Under the terms of the agreement, the Agency will pay escalating monthly payments through October 2024 and will have unlimited use of the space for that period of time. At lease inception, the lease liability is measured at the present value of the lease payments over the lease term. The Agency used a 3% imputed interest rate to calculate the present value of future cash flows in relation to the lease liability. The Agency recognized \$329,860 in operating lease expense related to this lease in 2023 and 2022.
- (B) The Agency has an operating lease agreement for several copiers. During 2020, the existing lease that was set to expire in November 2021 was terminated and a new lease was entered into. Under the terms of the 2020 agreement, the Agency will pay \$1,713 in monthly payments through July 2025 and will have unlimited use of the copiers for that period of time. At lease inception, the lease liability is measured at the present value of the lease payments over the lease term. The Agency used a 3% imputed interest rate to calculate the present value of future cash flows in relation to the lease liability. The Agency recognized \$29,331 and \$26,217 in operating lease expense related to this lease in 2023 and 2022, respectively.

United States Anti-Doping Agency

Notes to Financial Statements
December 31, 2023 and 2022

Future undiscounted cash flows for operating leases at December 31, 2023 are as follows:

2024	\$ 337,493
2025	<u>11,991</u>
Total future undiscounted lease payments	349,484
Less imputed interest	(5,115)
	<u>\$ 344,369</u>

Note 6: Liquidity

The Agency receives its funding from three key sources; a federal government grant, a contract with the U.S. Olympic and Paralympic Committee and contracted anti-doping services it provides to a variety of customers. There are no donor restrictions on funding.

As of December 31, 2023 and 2022, the following table shows the total financial assets held by the Agency that could readily be made available within one year of the statements of financial position date to meet general and operating expenses:

	2023	2022
Cash	\$ 4,851,745	\$ 5,691,154
Accounts receivable	1,089,218	1,022,062
Grants receivable	1,928,177	3,144,297
Investments convertible to cash in the next 12 months	<u>5,464,523</u>	<u>1,903,810</u>
Financial assets available to meet general expenditures within one year	<u>\$ 13,333,663</u>	<u>\$ 11,761,323</u>

The Agency has board-designated net assets, which are included in investments, for various purposes more fully described in Note 7. These could be made available to use within one year, as determined by the board, if necessary. Accordingly, these assets have been included in the quantitative information above.

The Agency regularly monitors liquidity required to meet its operating needs. Its liquidity strategy is to maintain sufficient liquid assets to cover 90 days of operations, maintain a high level of liquidity in all investments and operate as guided by the board approved budget.

United States Anti-Doping Agency

Notes to Financial Statements
December 31, 2023 and 2022

Note 7: Board-designated Net Assets Without Donor Restrictions

The Board has designated net assets for the following purposes:

	2023	2022
Research	\$ 1,000,000	\$ 1,000,000
Contingencies	<u>1,750,000</u>	<u>1,750,000</u>
	<u>\$ 2,750,000</u>	<u>\$ 2,750,000</u>

Note 8: USOPC Contract

The Agency has an agreement with the United States Olympic and Paralympic Committee (USOPC) to conduct a drug testing and anti-doping program for athletes in the Olympic, Paralympic and Pan American Games. During 2022, a new agreement was entered into through December 31, 2028. Support funded by the USOPC is recognized as the Agency performs the contracted services. Revenue received from the USOPC for the years ended December 31, 2023 and 2022 was \$6,600,000 and \$5,207,580, of which \$383,929 and \$263,519 was included in accounts receivable at December 31, 2023 and 2022, respectively. To mitigate the perceived conflict of interest between the Agency and the New Era ADR, Inc. in 2023 and the American Arbitration Association (AAA) in 2022 or the Court of Arbitration for Sport (CAS), which provides arbitration services for cases brought forth by the Agency, the USOPC directly pays all arbitration fees and expenses incurred by these entities up to a cap of \$500,000 and \$423,000 in 2023 and 2022, respectively. During 2023 and 2022, the USOPC directly paid arbitration costs to these entities of \$130,678 and \$156,730, respectively. If the arbitration expenses incurred are less than the cap, then the excess up to the cap is remitted to the Agency, which is included in the contract amount above. If the arbitration expenses incurred are more than the cap, then the excess is paid to the USOPC. At December 31, 2023 and 2022, there were excess amounts owed to the Agency.

Note 9: Revenue from Contracts with Customers

USOPC, Testing and Other Services Revenue

Performance obligations are determined based on the nature of the goods or services provided by the Agency in accordance with the contract. Revenue for performance obligations satisfied over time is recognized ratably over the period based on time elapsed. The Agency believes this method provides a faithful depiction of the transfer of services over the term of the performance obligation based on the inputs needed to satisfy the obligation.

United States Anti-Doping Agency

Notes to Financial Statements
December 31, 2023 and 2022

Transaction Price and Recognition

The Agency determines the transaction price based on standard charges for goods and services provided reduced by implicit price concessions provided to customers. The Agency determines its estimate of implicit price concessions based on its historical collection experience with this class of customers.

The Agency has determined that the nature, amount, timing and uncertainty of revenue and cash flows are affected by the following factors:

- Payers (for example, customer and others) that have different reimbursement and payment methodologies
- Geography of the service location

For the year ended December 31, 2023, the Agency recognized revenue from goods and services that transfer to the customer over time.

Contract Assets

The following table provides information about the Agency's receivables from contracts with customers:

	2023	2022
Accounts receivable, beginning of year	\$ 1,022,062	\$ 748,481
Accounts receivable, end of year	\$ 1,089,218	\$ 1,022,062

Note 10: Employee Benefit Plan

The Agency maintains a 401(k) benefit plan covering all employees who meet the eligibility requirements. The Agency makes contributions at its discretion. The Agency's contributions to the plan were \$491,339 and \$474,066 for the years ended December 31, 2023 and 2022, respectively.

United States Anti-Doping Agency

Notes to Financial Statements
December 31, 2023 and 2022

Note 11: Significant Commitments, Estimates and Concentrations

Accounting principles generally accepted in the United States of America require disclosure of certain significant estimates and current vulnerabilities due to certain concentrations. Those matters include the following:

Revenue Concentration

The Agency received 92% of its support during 2023 and 2022, from three organizations. As discussed in Note 8, the Agency has a contract with the USOPC (one of the three major organizations) through 2028.

Equipment Grant

Effective September 9, 2008, the Agency, as grantor, entered into a grant agreement with Sports Medicine Research and Testing Laboratory (the Laboratory). Under the terms of this grant agreement, the Agency will grant a piece of equipment with a cost of \$71,750 and now fully depreciated to the Laboratory. The Laboratory must use the equipment only for purposes that fit within the Agency's mission and must report the detail of testing performed with the equipment to the Agency each year. The Agency would have the right to take back the equipment if either of these requirements was not met. As such, management considers the equipment property of the Agency.

Investments

The Agency invests in various investment securities. Investment securities are exposed to various risks such as interest rate, market and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect the amounts reported in the accompanying statements of financial position.

Note 12: Subsequent Events

Effective January 1, 2024, the contract with Ultimate Fighting Championship was not renewed, which consisted of approximately 22% of contract revenue during 2023.

Subsequent events have been evaluated through May 30, 2024, which is the date the financial statements were available to be issued.

U S A D A

STANDING ON PRINCIPLE

PHONE (719) 785-2000
TOLL-FREE +1 (866) 601-2632
FAX (719) 785-2001
EMAIL USADA@USADA.ORG

USADA.ORG
TRUESPORT.ORG



U.S. Anti-Doping Agency